The economic importance of soybean (Glycine max) as a foodstuff has, in recent years, been supplemented by its importance as a source of bioactive compounds. Two of these compounds, the Bowman-Birk protease inhibitor (BBI) and the peptide lunasin, exhibit anti-cancer properties, and clinical studies suggest that the two may act in a complementary fashion. The present work surveys the levels of these two compounds across a time course of soybean development, a number of diverse soybean genotypes from the USDA Soybean Germplasm Collection, and a collection of soybean lines grown at Urbana and Bellflower, IL in the summer of 2012. Concentrations of BBI measured across mature lines in the study ranged from .101 to .38 mg/g defatted seed, while concentrations of lunasin ranged from 1.06 to 6.12 mg/g defatted seed. BBI and lunasin were significantly correlated through seed development (p = .0097), but concentrations of the compounds were not related in mature seeds. Genotype and the interaction of genotype by environment were found to significantly impact BBI (p = .03; p = .01), and this interaction effect was found to vary in direction depending on genotype. Environment (p = .03) and genotype had significant effects (p = .03; p < .01) on lunasin. Soil moisture may be the most important environmental factor in determining lunasin concentrations.
【 预 览 】
附件列表
Files
Size
Format
View
Environmental and genetic variation of the anti-cancer peptides lunasin and Bowman-Birk protease inhibitor in Glycine max